This vaccine is not subjected to direct genetic modification, instead, autologous antigen presenting cells (APCs) are cultivated in presence of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and prostatic acid phosphatase (PAP), an antigen expressed in prostate cancer tissue [51]. The gene discussed is ACP3; the disease is prostate carcinoma.